Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Pakistan Journal of Pharmaceutical Sciences. 2013; 26 (4): 827-830
em Inglês | IMEMR | ID: emr-126982

RESUMO

Exploring healing power in plants emerged in prehistory of human civilization. Sustaining good health has been achieved over the millions of years by use of plant products in various traditional sockets. A major contribution of medicinal plants to health care systems is their limitless possession of bioactive components that stimulate explicit physiological actions. Luckily Pakistan is blessed with huge reservoir of plants with medicinal potential and some of them; we focused in this study for their medicinal importance. In this study we checked the antibacterial activity inherent in Ricinus communis, Solanum nigrum, Dodonaea viscose and Berberis lyceum extracts for multidrug resistance bacterial strains Klebsiella pneumonae, E. coli and methyciline resistant Staphylococcus aureus. MRSA showed sensitivity for Ricinus communis. Multidrug resistant Klebsiella pneumonae was sensitive with Pine roxburgii and Ricinus communis but weakly susceptible for Solanum nigrum. Multidrug resistant E. coli was resistant to all plant extracts. Treatment of severe infections caused by the bacterial strains used in this study with Ricinus communis, Pine roxburgii and Solanum nigrum can lower the undesired side effects of synthetic medicine and also reduce the economic burden


Assuntos
Antibacterianos , Klebsiella pneumoniae , Escherichia coli , Staphylococcus aureus Resistente à Meticilina , Solanum nigrum , Berberis , Ricinus
2.
JPAD-Journal of Pakistan Association of Dermatologists. 2007; 17 (2): 105-111
em Inglês | IMEMR | ID: emr-128474

RESUMO

Mycophenolic acid [MPA] was introduced in the 1970s as a treatment for psoriasis, it has since been reformulated as mycophenolate mofetil [MMF]. With an improved side effect profile and enhanced bioavailability, MMF is a promising drug for immune-mediated skin diseases. It is currently approved for the prevention of organ rejection. Its list of dermatological indications continues to grow. As a noncompetitive inhibitor of inosine monophosphate dehydrogenase [IMPDH], MMF inhibits de novo purine synthesis. Its relative lack of hepatonephrotoxicity and perhaps low risk of carcinogenicity offer important therapeutic advantages. This new formulation showed enhanced bioavailability, tolerability and efficacy. No doubt case reports and case series of MMF therapy dominate the dermatologic literature; preliminary results are sufficiently promising to warrant larger, randomized clinical trials with this emerging therapy

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA